AU2017261292B2 - DNA monoclonal antibodies targeting IL-6 and CD126 - Google Patents

DNA monoclonal antibodies targeting IL-6 and CD126 Download PDF

Info

Publication number
AU2017261292B2
AU2017261292B2 AU2017261292A AU2017261292A AU2017261292B2 AU 2017261292 B2 AU2017261292 B2 AU 2017261292B2 AU 2017261292 A AU2017261292 A AU 2017261292A AU 2017261292 A AU2017261292 A AU 2017261292A AU 2017261292 B2 AU2017261292 B2 AU 2017261292B2
Authority
AU
Australia
Prior art keywords
ser
val
leu
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017261292A
Other languages
English (en)
Other versions
AU2017261292A1 (en
Inventor
David Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
The Wistar Institute
Original Assignee
University of Pennsylvania
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania, The Wistar Institute filed Critical University of Pennsylvania
Publication of AU2017261292A1 publication Critical patent/AU2017261292A1/en
Priority to AU2024203109A priority Critical patent/AU2024203109B2/en
Application granted granted Critical
Publication of AU2017261292B2 publication Critical patent/AU2017261292B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017261292A 2016-05-05 2017-05-05 DNA monoclonal antibodies targeting IL-6 and CD126 Active AU2017261292B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203109A AU2024203109B2 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
US62/332,377 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203109A Division AU2024203109B2 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Publications (2)

Publication Number Publication Date
AU2017261292A1 AU2017261292A1 (en) 2018-12-20
AU2017261292B2 true AU2017261292B2 (en) 2024-06-06

Family

ID=60203626

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017261292A Active AU2017261292B2 (en) 2016-05-05 2017-05-05 DNA monoclonal antibodies targeting IL-6 and CD126
AU2024203109A Active AU2024203109B2 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203109A Active AU2024203109B2 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Country Status (12)

Country Link
US (1) US20190192692A1 (enExample)
EP (1) EP3452106A4 (enExample)
JP (3) JP7311113B2 (enExample)
KR (3) KR20250011241A (enExample)
CN (1) CN109789224A (enExample)
AU (2) AU2017261292B2 (enExample)
BR (1) BR112018072697A2 (enExample)
CA (1) CA3023089A1 (enExample)
EA (1) EA201892524A1 (enExample)
MX (2) MX2018013523A (enExample)
SG (2) SG10202011023YA (enExample)
WO (1) WO2017192933A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3534941A4 (en) * 2016-11-07 2020-07-08 The Wistar Institute Of Anatomy And Biology CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST LYME DISEASE
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093894A2 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2632628C (en) * 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
WO2008019061A2 (en) * 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
JP2011520898A (ja) * 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8992908B2 (en) * 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015054293A1 (en) * 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093894A2 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Also Published As

Publication number Publication date
AU2017261292A1 (en) 2018-12-20
JP2019518074A (ja) 2019-06-27
JP2023086734A (ja) 2023-06-22
KR20190031439A (ko) 2019-03-26
JP7311113B2 (ja) 2023-07-19
BR112018072697A2 (pt) 2019-02-19
WO2017192933A1 (en) 2017-11-09
KR20250011241A (ko) 2025-01-21
EP3452106A4 (en) 2020-01-08
JP2025147175A (ja) 2025-10-06
AU2024203109A1 (en) 2024-05-30
CN109789224A (zh) 2019-05-21
US20190192692A1 (en) 2019-06-27
AU2024203109B2 (en) 2026-05-21
EP3452106A1 (en) 2019-03-13
MX2025009846A (es) 2025-09-02
KR20230058733A (ko) 2023-05-03
SG10202011023YA (en) 2020-12-30
EA201892524A1 (ru) 2019-04-30
SG11201809786TA (en) 2018-12-28
CA3023089A1 (en) 2017-11-09
MX2018013523A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
AU2017261374B2 (en) DNA antibody constructs for use against pseudomonas aeruginosa
KR20170087486A (ko) 일반 경쇄 및 이의 사용 방법
AU2017276726B2 (en) Herpesvirus with modified glycoprotein D
AU2024203109A1 (en) DNA monoclonal antibodies targeting IL-6 and CD126
KR20220117915A (ko) 항-muc1 조성물 및 사용 방법
KR20230125851A (ko) 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론항체
US20240376179A1 (en) Dna antibody constructs for use against middle east respiratory syndrome coronavirus
JP2023126321A (ja) ライム病に対する使用のためのｄｎａ抗体構築物
US20240287166A1 (en) Dna antibody constructs for use against plasmodium parasites
US20230340082A1 (en) Dna antibody constructs for use against rotavirus
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
HK40009046A (en) Dna monoclonal antibodies targeting il-6 and cd126
HK40013455A (zh) 用於针对莱姆病的dna抗体构建体
US20210047388A1 (en) Nucleic acid antibody constructs for use against ebola virus
EA042308B1 (ru) Днк-моноклональные антитела, нацеленные на il-6
WO2019152602A1 (en) Structurally modified flavivirus dmabs
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
HK40009043A (zh) 靶向检查点分子的dna单克隆抗体
WO2022173745A1 (en) Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same
HK40009739A (en) Dna antibody constructs and method of using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)